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Abstract: The Paramyxoviridae genus Henipavirus is presently represented by the type 
species Hendra  and Nipah  viruses which are both recently emerged zoonotic viral 
pathogens responsible for repeated outbreaks associated with high morbidity and mortality 
in Australia, Southeast Asia, India and Bangladesh. These enveloped viruses bind and enter 
host target cells through the coordinated activities of their attachment (G) and class I fusion 
(F) envelope glycoproteins. The henipavirus G glycoprotein interacts with host cellular B 
class ephrins, triggering conformational alterations in G that lead to the activation of the F 
glycoprotein, which facilitates the membrane fusion process. Using the recently published 
structures of HeV-G and NiV-G and other paramyxovirus glycoproteins, we review the 
features of the henipavirus envelope glycoproteins that appear essential for mediating the 
viral fusion process, including receptor binding, G-F interaction, F activation, with an 
emphasis on G and the mutations that disrupt viral infectivity. Finally, recent candidate 
therapeutics for henipavirus-mediated disease are summarized in light of their ability to 
inhibit HeV and NiV entry by targeting their G and F glycoproteins. 
Keywords: paramyxovirus; entry; attachment glycoprotein; fusion glycoprotein; membrane 
fusion; receptor; ephrin-B2; ephrin-B3; inhibitor; antibody; immunotherapy 
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1. Introduction  
Hendra virus (HeV) and Nipah virus (NiV) are enveloped, negative sense single-stranded RNA 
viruses that were first identified in the mid 1990s following two separate outbreaks in Australia and 
Malaysia, respectively [1–3]. Both outbreaks began as zoonotic respiratory infections in either horses 
(HeV) or swine (NiV) that were transmitted to humans in close contact with infected animals 
(reviewed in [4]). For both HeV and NiV the initial symptoms in infected humans manifest ~1 to 2 
weeks post infection with fever, chills, headache and myalgia but can progress to severe respiratory 
distress and/or acute encephalitis [1,5–10]. Both NiV and HeV can also cause relapsed encephalitis in 
infected individuals several months to several years following recovery from acute infection [11–13].  
In nature both HeV and NiV are found in several pteropid fruit bat species (flying foxes) [14], but the 
routes of transmission to humans are different as HeV is transmitted from bats-to-horses and then to 
humans, while NiV transmission has been from bats-to-pigs and then to humans and also directly from 
bats-to-humans as well as humans-to-humans [15–18] (reviewed in [19]).  
Only sporadic outbreaks of HeV occurred in the years immediately following its initial recognition 
in 1994, but starting in 2006 annual outbreaks of HeV have occurred among the equine population in 
Australia, resulting in a total of seven human cases with four fatalities [8,20]. However, in 2011 (June 
to October) an unprecedented number of eighteen independent outbreaks of HeV among horses in 
Australia was reported, culminating in the death or euthanasia of 23 horses, 1 dog and the close 
monitoring of more than 60 individuals for HeV infection [21,22]. Similarly, following the first 
outbreak in Malaysia and Singapore in 1998, almost annual outbreaks of NiV infection with high 
human case fatality rates (~70%) have been recorded primarily in Bangladesh but also India (reviewed 
in [23,24]). To date, there have been a total of 564 reported cases of NiV infection in people of which 
299 have been fatal (reviewed in [23]). The repeated occurrences of henipavirus outbreaks among 
people and animals has demonstrated the importance for developing both intervention and 
countermeasure strategies to prevent cases of human infection [25–27].  
While outbreaks of HeV and NiV have been contained to Australia (HeV) and Malaysia, Bangladesh 
and India (NiV), additional serological and limited nucleic acid evidence suggests that antigenically 
related henipaviruses are circulating in other regions including Thailand, Indonesia, China, Madagascar 
and West Africa [28–34]. Further serological evidence (cross-reactive antibodies to NiV glycoproteins) 
has also suggested that henipavirus transmission to domestic pigs in West Africa is possible [35]. In 
addition to the apparent widespread occurrence of the henipaviruses in various bat species, and unlike 
all other paramyxoviruses, HeV and NiV possess a broad host tropism that includes pigs, horses, cats, 
dogs, guinea pigs, hamsters, ferrets, monkeys and humans, leading to the classification of HeV and NiV 
into the new genus henipavirus in the family Paramyxoviridae [36]. Given the high morbidity and 
mortality rates associated with henipavirus infections in both humans and livestock, their recognized 
natural reservoirs in nature, the ease of propagation and a lack of any licensed vaccines or therapeutics, 
HeV and NiV pose significant biosecurity threats and are classified as biosafety level-4 (BSL-4) pathogens.  
Virus attachment, membrane fusion and particle entry for HeV and NiV requires two distinct 
membrane-anchored glycoproteins: an attachment glycoprotein (G) and a fusion glycoprotein (F). The 
G glycoprotein is required for receptor binding and virion attachment to the host cell, and the F 
glycoprotein is directly involved in facilitating the merger of the viral and host cell membranes.   Viruses 2012, 4  
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As HeV-G and -F share a high degree of similarity with NiV-G and -F (approximately 83% and 89% 
amino acid identity for G and F, respectively), it also seems reasonable that the characteristics and 
features attributed to the viral glycoproteins of one virus may be representative of the corresponding viral 
glycoproteins of the other virus [37]. 
2. Attachment Glycoprotein (G) 
Most of the well-described paramyxoviruses possess a multifunctional hemagglutinin–neuraminidase 
(HN) glycoprotein which binds the virions to sialic acid receptors on host cells, whereas some others, 
such as the morbilliviruses including measles virus (MeV), have an H attachment glycoprotein, which 
possesses only hemagglutinating activity, and uses the membrane proteins CD46 or CD150/SLAM as 
receptors, depending on the virus strain (reviewed in [38,39]). Recently, the adherens junction 
membrane protein nectin-4 on human epithelial cells has also been shown to be an important receptor 
for MeV [40,41]. Like the HN and H glycoproteins, the henipavirus attachment G glycoprotein is a 
type II transmembrane protein that consists of an N-terminus cytoplasmic tail, a transmembrane 
domain, a stalk domain and a globular head; however the G glycoprotein possess neither hemagglutinin 
nor neuraminidase activities. The globular head folds as a β-propeller with a central cavity surrounded 
by six blades, which themselves are composed of four anti-parallel beta sheets [42–44]. The β-propeller 
shape is maintained by disulfide bonds between beta sheets in each blade as well as two additional 
disulfide bonds between blades three and four and between the N- and C-termini of the globular head. 
Five potential N-linked glycosylation sites (N306, N378, N417, N481 and N529) have been identified 
in the globular head of NiV, and evidence has verified that four of the five sites are glycosylated with 
one site, N417, yielding variable reports likely owing to alternative expression methods [43–45]. 
Likewise, the HeV-G head domain also has the same five predicted and conserved N-linked 
glycosylation sites occupied by carbohydrate moieties [46]. Detailed glycan composition and site 
occupancy analysis of the entire ectodomain of HeV-G has recently been performed and has also 
revealed O-linked glycosylation sites in the protein [47]. 
2.1. Oligomerization of G Glycoprotein 
The native conformation of G when expressed on the virion or the surface of an infected cell is a 
tetramer, which is comprised of a dimer of dimers [44,48]. Residues responsible for the 
oligomerization of G are isolated to the stalk domain as expression of the globular head alone results 
only in monomeric species [44]. Further investigation determined that two disulfide bonds in the stalk 
domain of G enable dimer formation, but the specific interactions in the stalk domains between 
homodimers that enable G to form a tetramer are unknown [48]. Bowden et al. proposed that one 
surface of dimer-dimer interface occurs across the β1- and β6-propellers of the globular head [44,45]. 
This suggestion is supported by the lack of both structural divergence and N-glycosylation sites, which 
would interfere with oligomerization, along this section of the protein. Additionally, the recently 
reported structure and model of a tetrameric Newcastle disease virus (NDV) HN has provided further 
insight on the organization and oligomeric structure of a paramyxovirus attachment glycoprotein. The 
stalk domains of NDV-HN form a four-helix bundle (4 HB) with a hydrophobic core that is the result 
of an 11-residue repeat domain in the stalk [49]. Similarly to NDV-HN, HeV and NiV-G stalks contain Viruses 2012, 4  
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alpha helices with a predicted break from amino acids 95–98, and the modeled juxtaposition of these 
stalks with the globular heads of HeV-G resembles the tetrameric structure of NDV-HN (Figure 1).  
Figure 1. Model of the Hendra virus attachment G glycoprotein. The HeV-G ectodomain is 
shown in its dimer conformation. The secondary structure elements of the two globular 
head domains, colored in green and blue, are derived from the crystal structure, which also 
revealed the five predicted N-linked glycosylation sites (N306, N378, N417, N481 and 
N529) occupied by carbohydrate moieties (gray spheres) [46,47]. However, N378 was not 
modeled in the figure due to weak electron density. The G glycoprotein head domain folds 
as a six-blade β-propeller with disulfide bonds illustrated as yellow sticks. The residues of 
the ephrin-B2 G-H loop are shown in yellow. While the entire structure of the HeV-G stalk 
domain (residues 71–173) has not been determined, residues 77–136 are modeled for each 
monomer suggesting this region forms a discontinuous helix (Helix Break) [50]. The 
position of the HeV-G head dimer and stalks are oriented based on the alignment with the 
NDV structure and the receptor binding face of the blue monomer is facing out and the 
green monomer is facing left. Despite having two helical ranges, Thr-77 to Lys-95 and 
Thr-98 to Ser-135, the HeV-G stalk residues 98–135 appear equivalent to the HN 
glycoprotein stalk helix domain of the recently reported NDV structure [49]. Additionally, 
the Ile residues in the HeV-G stalk domain that can modulate conformational changes 
associated with receptor binding are indicated and are located in the alpha helical region of 
the HeV-G stalk domain that aligns with the NDV-HN stalk [51]. 
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A model of a tetrameric parainfluenza 5 virus (SV5) HN previously reported suggested a tetramer 
formation in which the globular heads of the two dimers were in contact [52], which contrasts with the 
more recent structural data of the NDV tetramer in which the globular heads of the dimers are 
separated [49]. Although the globular head dimer of NDV and SV5 can be superimposed with a low 
1.5 Å root mean square deviation (rmsd), the earlier SV5 tetramer model is not in accord with the 
recent NDV dimer and stalk configurations. Given the characteristics of HeV and NiV-G, specifically 
the location of the N-linked glycosylation sites and the predicted stalk helices, it seems reasonable that 
the tetrameric form of the henipavirus G glycoprotein would also resemble the NDV-HN structural 
model (Figure 1).  
3. Receptors Ephrin-B2 and Ephrin-B3 
The henipaviruses are the most recently recognized paramyxoviruses that also use host cell 
membrane proteins as virus entry receptors, and both HeV and NiV bind to ephrin-B2 and ephrin-B3 
via their G glycoproteins [53–56]. Human ephrin-B2 and ephrin-B3 are 39% identical in amino acid 
sequence and are members of a large family of surface expressed glycoprotein ligands that bind to Eph 
receptor tyrosine kinases and mediate bi-directional cell-cell signaling events within the nervous, 
skeletal and vascular systems [57,58]. The ephrin-B2 and -B3 molecules are highly conserved proteins 
across species with amino acid identities ranging from 95–96% and 95–98%, respectively, including 
those hosts susceptible to henipavirus infection such as human, horse, pig, cat, dog and flying foxes [59].  
Ephrin-B2 is found in arteries, arterioles and capillaries in multiple organs and tissues including 
arterial smooth muscle and human bronchiolar epithelial cells but appears absent from venous 
components of the vasculature [60], whereas ephrin-B3 is found predominantly in the nervous system 
and the vasculature (reviewed in [61,62]). The identification of ephrin-B2 and ephrin-B3 as functional 
receptors for the henipaviruses in cultured cells provides some explanation for both the broad species 
tropisms of the viruses, owing to their highly conserved nature, and the observed distribution of   
viral antigen in arterial endothelial cells, smooth muscle, neurons, and some epithelial cells   
(reviewed in [63,64]).  
While it is unclear how many ephrin molecules are required to bind oligomeric G to activate the 
henipavirus membrane fusion process, recent structural data has revealed that a G glycoprotein head 
domain (monomeric) binds an ephrin molecule in a 1:1 ratio [42,43,46]. Both ephrin-B2 and ephrin-B3 
are able to support productive infection of HeV and NiV, but the binding affinities of HeV and NiV-G 
for ephrin-B2 and -B3 are uncertain and this is also complicated by the oligomeric nature of both the G 
glycoprotein and the ephrins. One report has suggested HeV and NiV-G have the same binding affinity 
for ephrin-B3 while NiV-G has a higher affinity for ephrin-B2 than HeV-G; however another study 
indicated that HeV and NiV-G bound ephrin-B2 similarly while NiV-G engaged ephrin-B3 with a 
higher affinity in comparison to HeV-G [59,65,66]. One possible explanation to explain these different 
findings is that two different HeV-G sequences were used. Negrete et al. determined that the sequences 
of two HeV-G strains currently used in research contain one amino acid change at position 507, having 
either a Ser or a Thr [66]. A Thr at position 507 confers ephrin-B3 affinity similar to that of NiV-G, 
but a Ser at position 507 reduces the affinity of HeV-G for ephrin-B3 while having no affect on  
ephrin-B2 affinity. Given the physiological locations of ephrin-B2 and -B3, the observed differences in Viruses 2012, 4  
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the transmissibility of HeV and NiV and the differences in HeV and NiV disease course in susceptible 
hosts upon infection, additional study of the henipavirus G glycoproteins and their interaction with the 
ephrin receptors will further our understanding of the biology and pathology of these important 
zoonotic agents.  
3.1. Interaction of Henipavirus G with Ephrin Receptors 
B-class ephrins contain a globular domain that is comprised of eight β-strands (identified as A-D,  
F-H and K) surrounding a hydrophobic core [67]. Although there are three B-class ephrins (B1-B3) 
with high levels of similarity, only ephrin-B2 and ephrin-B3 are able to serve as functional receptors 
for HeV and NiV. The major structural divergence between these ephrins occurs in the G-H loop, 
which is a 15 amino acid linker region between β-strands G and H that is also primarily responsible for 
the binding between ephrins and their cognate Eph receptors [68].  
Despite the 15-amino acid length of the G-H loop, only a short stretch of conserved amino acids 
(F/Y117/120SPNLW122/125) binds in the groove of the globular head of HeV and NiV-G with the only 
difference between ephrin-B2 and ephrin-B3 being F117 and Y120, respectively [42,43,68]. (To avoid 
confusion, we will use the ephrin-B3 numerical designation for the G-H loop residues, identified as 
F/Y120-W125). Preceding the solution structures of the henipavirus G glycoproteins in complex with 
ephrin-B2 and -B3, the importance of the ephrin G-H loop was first hypothesized by Negrete et al. and 
confirmed by mutagenesis that involved the conversion of two residues in the G-H loop of ephrin-B1 
to the residues in ephrin-B2, making ephrin-B1 a functional NiV receptor [55]. The ephrin-B1 amino 
acid replacements L124→Y and W125→M would result in steric clashes and converting these 
residues to match the ephrin-B3 sequence eliminates this hindrance [55]. The overall conformation and 
flexibility of the ephrin-B2 and ephrin-B3 G-H loops might also influence receptor selectivity of the 
henipavirus G glycoproteins. Indeed, both ephrin-B2 and -B3 appear to have G-H loops with extended 
and relatively rigid conformations, whereas ephrin-B1 has a more flexible G-H loop, which may not be 
compatible with the apparent lock-and-key ephrin/G glycoprotein binding mechanism [69]. 
Binding between ephrin-B2 and HeV and NiV-G occurs in two regions that occlude approximately 
2,700 Ǻ
2 surface area on the interface [42,43]. The first region occurs along a mostly polar area of the 
outer rim of the cavity in the globular head of the henipavirus G and requires 24 hydrogen bonds, four 
salt bridges and multiple hydrophobic interactions [42,43]. The second region primarily involves 
interaction through van der Waals forces of the ephrin G-H loop residues F/Y120, P122, L124 and 
W125 with binding pockets in the central cavity of the globular head of G [42,43]. The four binding 
pockets in HeV and NiV-G for the residues in the ephrin-B2 and -B3 G-H loop are highly conserved 
with only four differences, the most notable being a Val (NiV) to Thr (HeV) change at position 507 
[42] (Table 1).  
The crystal structures of both HeV and NiV-G in complex with ephrin-B2 have provided much 
information on the specific interaction between these attachment glycoproteins and receptor, but 
whether relevant conformational changes must occur for G/ephrin-B2 binding is not completely clear. 
It is generally accepted that the G-H loop of ephrin-B2 and -B3 does not undergo major 
conformational change, except for rearrangements of W125 upon G engagement that are suggested to 
“latch” ephrin-B2 into a stronger association [46].  Viruses 2012, 4  
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Table 1. Henipavirus G glycoprotein receptor binding pockets. The residues in HeV-G and 
NiV-G that form the binding pockets for the residues of the ephrin-B2 and ephrin-B3 G-H 
loop are shown. The residues are highly conserved with those in bold-face indicating the 
four amino acids that are different between the HeV-G and NiV-G binding pockets for 
Eprhin-B2 and -B3 P122, L124 and W125. 
Binding Pocket for loop residues  HeV-G glycoprotein residues  NiV-G glycoprotein residues 
F/Y 
C240, N557, A558, Q559, E579, 
I580, Y581, I588, R589 
C240, N557, A558, Q559, E579, 
I580, Y581, I588, R589 
P 
P488, G489, Q490, E505, G506, 
T507, Q530, T531, A532 
P488, G489, Q490, E505, G506, 
V507, Q530, T531, A532 
L  Y458, W504, E505, G506  F458, W504, E505, G506 
W  L305, V401, N402, W504  L305, I401, R402, W504 
 
While there is debate as to whether major or minor conformational changes occur in the monomeric 
henipavirus G head domain upon receptor binding, it is clear that some limited structural rearrangements 
do occur but appear restricted to a specific region [42,43]. Three of the binding pockets in the HeV and 
NiV-G head domain (pockets for ephrin-B2 and -B3 residues P122, L124 and W125) undergo little 
conformational change, while the G glycoprotein D579-P590 loop (binding pocket for ephrin-B2 and  
-B3 F117 and Y120, respectively) appears to have the greatest structural alteration upon receptor 
binding [44]. Interestingly, this region is the one binding pocket that must accommodate two different 
residues, suggesting ephrin-B2 and -B3 bind to HeV and NiV-G by an induced-fit model as the F 
residue binding pockets in each henipavirus G glycoprotein must conform in a way to accommodate 
the different residues in the G-H loops of ephrin-B2 and ephrin-B3 [44,45]. Other more recent data 
suggest that ephrin-B2 binding to HeV-G supports a “lock, key and latch” model for the association 
between the G glycoprotein and its receptors with the W122 residue of ephrin-B2 serving as the 
“latch” [46]. Finally, it should also be recognized that the available structural data of a henipavirus G 
glycoprotein complexed with an ephrin receptor is from monomeric proteins and do not take into 
account the possibility of broader oligomeric changes that may occur following receptor engagement. 
For example, in case of MeV-H, it was recently reported that following receptor binding, the two heads 
of a MeV-H dimer move in relation to each other, and by stabilizing the H-dimer interface by   
inter-molecular disulfide bonds, fusion can be blocked, suggesting that oligomeric H conformational 
changes (dimer separation or movement) is linked to fusion triggering [70].  
3.2. Mutations in the G Glycoprotein That Impact Function 
As might be expected, mutational studies have highlighted a number of residues in both the HeV 
and NiV-G glycoproteins and the ephrin-B2 and -B3 receptors that are critical for their interaction. The 
majority of reported mutations in the G glycoprotein that affect function (i.e., the protein’s fusion 
promoting activity in the context of co-expressed F glycoprotein) are conserved between HeV and NiV 
and are located throughout the globular head and stalk domains. Mutations located in the globular head 
that decreased fusion activation by at least 25%–50% can be separated into two groups based on their 
location in the globular head—distal or proximal to the ephrin binding site. Group 1 residues (D257A, 
D260A, K443A, G449A, K465A and D468A) are located closer to the stalk domain of the henipavirus Viruses 2012, 4  
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G glycoprotein, and are distant from the ephrin binding site, but despite this lack of proximity, all of 
these Group 1 mutants display reduced binding to both ephrin-B2 and -B3 [56]. Given the distance 
between the locations of these mutations and the receptor binding site, it is unlikely that the mechanism 
of reduced binding is due to steric hindrance/blocking of the binding site. Bishop et al. proposed that 
these mutations could act by locking HeV-G in a conformation that favors binding to HeV-F but not 
ephrin-B2 as these mutants demonstrated an increase in HeV-F co-association [56]. A re-examination 
of some of these mutations in the context of the crystal structure of the dimeric interface of HeV-G 
provides some additional insight (Figure 2). As can be seen from the figure, mutants D257A and 
D260A appear to be involved in interaction between the two globular heads of the dimer, and disruption 
of the homodimer could lead to decreased receptor binding and resultant fusion activation (Figure 2A). 
Additionally, using the data reported by Yuan et al. on the NDV-HN tetrameric structure [49], modeling 
the location of the HeV-G stalk domain to examine the impact of the Group 1 mutants reveals that 
residues G449 and D468 appear to interact with the stalk domain. Some conformational changes in G 
occur upon receptor binding, and therefore HeV-G would have pre-receptor-bound and post-receptor-
bound forms with structural differences in either the head or stalk (or both) domains. The importance 
of the HeV-G stalk domain in the context of its fusion promoting activity and role in the maintenance 
of the protein’s conformation is discussed below (Section 5). Mutation of either G449 or D468 could 
destabilize the pre-receptor-bound structure of HeV-G and interfere with receptor binding and/or 
receptor-triggered conformational changes required for its fusion promoting activity (Figure 2B). The 
final two mutants in Group 1 (K443A and K465A) are both located in a region of HeV-G that is part of 
a massive hydrogen bond network, which adds stability to the structure of HeV-G (Figure 2A). 
Mutation of these residues likely destabilizes this hydrogen bond network, preventing HeV-G from 
obtaining the correct conformation required for receptor binding and fusion. See Table 2 for a 
summary of mutant Groups. 
The Group 2 residues (N402A, Q490A, E501A, W504A, E505A, Q530A, T531A, A532K, E533Q, 
N557A, Y581A and I588A) are located on the outer surface of the globular head near the ephrin 
binding site and can be further broken down into 3 sub-groups based on receptor usage in the context 
of either HeV or NiV-G [46,66,71] (Figure 2C and Table 2). The first sub-group (Group 2a) includes 
those residues that decreased fusion promoting activity by decreased receptor binding without knowing 
which ephrin receptor was used, and these mutations are Q530A, T531A, A532K and N557A [71]. 
The second and third sub-groups (Subgroups 2b and 2c) contain mutations that decrease the fusion 
promoting activity of G upon either ephrin-B2 usage (N402A, E501A, E505A, G506A, E533A, 
Y581A and I588A) or ephrin-B3 usage (N402A, Q490A, E501A, W504A, E505A, G506A, E533A, 
Y581A and I588A) respectively [46]. These two sub-groups of mutated residues are quite similar with 
only the additional Q490A and W504A mutations in Subgroup 2c that exhibit decreased fusion 
promoting activity in the context of HeV-G and ephrin-B3 interaction. Interestingly, the residues of 
Subgroup 2b had no apparent decrease in ephrin-B2 binding but were significantly impaired in 
supporting fusion promoting activity as measured by pseudotyped virus entry, whereas the majority of 
mutations in Subgroups 2a and 2c had decreased receptor binding. These findings were in good 
agreement with earlier observations that mutation of residues W504 and E505 impair ephrin-B3 
binding and virus entry and mutation of E533 impairs both ephrin-B2 and -B3 usage [66]. In the 
context of HeV-G mutations, E505A also revealed impaired ephrin-B2 usage by virus entry but little Viruses 2012, 4  
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effect on impaired binding, and mutation E533A, which abrogated both ephrin-B2 and -B3 usage in 
virus entry, had little effect on binding ephrin-B2 [46]. Only two mutations in Subgroup 2c (N402A 
and I588A) possess significant impairment of HeV-G function but have no decrease in ephrin-B3 
receptor binding. Interestingly, among the Group 2 mutants, only two of these residues (E501 and 
E533) are not directly involved in forming binding pockets for the G-H loop of ephrin-B2 or -B3. 
Figure 2. Mutations in HeV-G that affect fusion promoting activity. (A) Residues A257, 
A260, A443 and A465 that decrease HeV fusion when mutated are highlighted in red in the 
HeV-G globular head dimer. Based on the location of residues A257 and A260, it is likely 
they are necessary for interaction between the two globular heads, while residues A443 and 
A465 are centrally located in the globular head in a region of extensive hydrogen bonding. 
(B) The predicted structure of an HeV-G dimer with globular heads and stalk domains is 
shown with residues G449 and D468 highlighted in red. These two residues are located in 
proximity to the stalk domain, and mutation of these residues decreases HeV fusion, 
suggesting they may be involved in interactions between the globular heads and stalk 
domains that are essential for the fusion process. (C) Monomeric units of the globular head 
of HeV-G (gray) are shown in complex with the G-H loop residues FSPNLW of ephrin-B2 
(yellow). Mutant Group 1 residues that decrease fusion are located further from the ephrin-
B2 binding site and are shown in green. Mutant Group 2 residues that decrease fusion are 
shown in blue and cluster around the ephrinB2 binding site. Residues that enhance fusion 
(Group e1) are shown in red and are also distally located from the ephrin-B2 binding site. 
Given the divergent locations of the mutations that affect fusion, these mutations likely use 
different mechanisms, such as disrupting HeV-G structure or preventing ephrin-B2/B3 
binding, to prevent HeV fusion. 
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Figure 2. Cont. 
 
Table 2. Summary of HeV-G Mutants that affect fusion. Mutations that either decrease or 
increase HeV-mediated fusion are separated into various groups based on their location in 
the globular head (distal or proximal to ephrin-binding site) or stalk domain of HeV-G, 
which receptor is bound and whether the mutation affects receptor binding. Information 
supplied in the Notes column is based on the modeled structures of HeV-G head and stalk 
domains or obtained from experimental data as indicated. Squares shaded in gray represent 
information that is unknown or not relevant.  
Effect Location  Group Subgroup Residues  Binds  Notes 
Decrease 
Globular 
Head—
Distal 
Group 
1 
 
D257, D260 
 
Disrupts dimer 
1 
G449, D468  Disrupts stalk-head interaction 
1 
K443, K465  Disrupts hydrogen bonding 
1 
Globular 
Head—
Proximal 
Group 
2 
Subgroup 2a 
Q530, T531, 
A532, N557 
Unknown  Decreased receptor binding 
2 
Subgroup 2b 
N402, E501, 
E505, G506, 
E533, Y581, 
I588 
Ephrin-B2 No  disruption in receptor binding 
2 
Subgroup 2c 
Q490, E501, 
W504, E505, 
G506, E533, 
Y581 
Ephrin-B3 
Decreased receptor binding 
2 
N402, I588  No disruption in receptor binding 
2 
Stalk 
Group 
3 
 
I101, I105, I112, 
I120, I124, I131, 
I138, I155, I160 
  No disruption in receptor binding 
2 
Increase 
Globular 
Head 
Group 
e1 
Subgroup e1 
D564, D470 
Unknown 
No disruption in receptor binding 
2 
G439  Decreased receptor binding 
2 
Subgroup e2 
V401, Q490, 
Q559  Ephrin-B2 
No disruption in receptor binding 
2 
W504  Decreased receptor binding 
2 
Subgroup e3  V401, Q559  Ephrin-B3  No disruption in receptor binding 
2 
1 Predictions based on modeled structure of HeV-G head and stalk domains; 
2 Experimental data. Viruses 2012, 4  
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Group 3 mutations include a series of isoleucine residues in the stalk region of HeV-G (I101A, 
I105A, I112A, I120A, I124A, I131A, I138A, I155A and I160A) that also resulted in significant 
decreases in fusion promoting activity while having no effect on receptor binding, leading Bishop et al. 
to speculate that these residues are important for maintaining the conformational integrity and stability 
of the G glycoprotein as it relates to regulating the G-F interaction and its fusion promoting   
activity [51]. The region of the stalk domain that contains these residues is shown in Figure 1, and the 
implications of these mutations will be discussed below.  
Although the majority of mutations introduced in HeV and NiV-G resulted in decreased levels of 
fusion promoting activity, there were a few residues located in the globular head that enhanced fusion 
promoting activity upon mutation (Group e1) (Table 2). Again, these mutations can be divided into 
three groups based on their use of specific ephrin receptors. The first fusion-enhancing (e) group 
(Subgroup e1) of mutants (G439A, D564A and D470A) increased fusion promoting activity, although 
it was unknown which receptor was used for infection [56]. Interestingly, mutant G439A exhibited 
increased fusion promoting activity along with decreased receptor binding capacity. Fusion-enhancing 
Subgroups e2 and e3 contain mutants that increased fusion with ephrin-B2 (V401A, Q490A, W504A 
and Q559A) or ephrin-B3 (V401A and Q559A), respectively [46]. As might be expected the vast 
majority of these mutations in Subgroups e2 and e3 had no effect on receptor binding with the only 
exception being residue W504A in Subgroup e2 that had decreased receptor binding.  
Comparing some of the mutations using pseudotyped virus entry it was discovered that two 
mutations had opposite effects depending on whether the ephrin-B2 or ephrin-B3 receptor was utilized. 
Mutations Q490A and W504A both decrease the fusion promoting activity of G in ephrin-B3 
dependent virus entry but also revealed enhanced virus entry in the context of ephrin-B2. Q490A is 
able to bind ephrin-B2 with an enhanced pseudotyped virus entry result but was unable to efficiently 
bind ephrin-B3, which resulted in a significant impairment of virus entry [46]. Further, HeV-G mutant 
W504A was notably impaired in binding both ephrin-B2 and ephrin-B3 in comparison to wild-type 
HeV-G; however this mutant has enhanced virus entry with ephrin-B2 expressing target cells.  
Finally, the importance of the G-H loop in ephrin-B2 and -B3 was first identified by Negrete et al. 
when the Leu and Trp residues in this solvent exposed loop were found critical for NiV binding and 
entry (described above) [55]. These authors also followed up these findings with NiV-G mutagenesis 
and identified several key residues in the receptor binding region of G that are critical for ephrin-B2 
and/or ephrin-B3 binding [66]. The structures of the ephrin-B2 and -B3 complexes with   
henipavirus G glycoproteins are now known with the critical residues in the G-H loop indentified 
(F/Y117/120SPNLW122/125), and these residues have also been explored by mutagenesis in the context of 
ephrin-B2 [72]. Surprisingly, mutating four of these residues (S121, P122, L124 and W125) to an 
alanine increased the infectivity of NiV-F and -G pseudotyped virus, while F120A was the only   
ephrin-B2 mutant that decreased NiV pseudotyped virus infectivity [72]. Additional studies revealed 
that the enhanced infectivity of L124A was due to an increase in the binding between the ephrin-B2 
L124A mutant and virus in comparison to wild-type ephrin-B2, while the increased infectivity of the 
other mutations where thought to be due to an increased plasticity in the G-H loop or the loss of steric 
hindrance in the binding pockets of NiV-G [72]. No single mutation could completely abrogate NiV 
pseudotyped virus infectivity suggesting that multiple residues in ephrin-B2 are important for interaction 
with NiV-G.  Viruses 2012, 4  
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Taken together, these mutations in both HeV and NiV-G and the ephrin receptor reveal an 
interesting perspective of the conformational changes that may be required for henipavirus envelope  
glycoprotein-mediated membrane fusion. Based on the predictive modeling of the HeV-G globular 
head dimer with the stalk domains (Figure 1), it seems clear that prior to receptor binding, HeV-G 
must be in a required pre-receptor-bound conformation, and disruption of this conformation, whether 
through disturbance of the dimer interface or the interaction of the globular head with the stalk, could 
have deleterious effects on receptor binding and the fusion promoting activity of G. Furthermore, it is 
also clear that ephrin-B2 and -B3 binding alone does not appear to be sufficient for triggering fusion 
because a number of HeV-G mutants are fully capable of binding ephrins but are completely blocked 
in promoting fusion. All together these observations suggest the existence of intermediate steps, 
initiated by receptor binding, that alter the conformation of G required for its fusion promoting 
activity. For example, the HeV-G mutant I588A is able to bind to both ephrin-B2 and -B3 to an equal 
if not better extent than wild-type HeV-G, yet it is unable to support pseudotyped virus entry, 
suggesting that important residues can be identified that appear to uncouple host cell/ephrin attachment 
and viral fusion initiation [46]. The observation that receptor binding and F triggering can be separated 
has also been made earlier with the MeV-H and -F glycoproteins [73,74]. This uncoupling of receptor 
binding and fusion initiation is further supported by the mutations in the HeV-G stalk domain, which 
also have no effect on receptor binding but are completely abrogated in supporting fusion [51]. These 
findings and the G glycoprotein mutants will be important tools for additional functional and structural 
analysis of the precise molecular steps underlying the receptor triggering mechanism of henipavirus 
entry and how such mutations in the G glycoprotein accomplish this functional block. 
4. Fusion Glycoprotein (F) 
While the G glycoprotein is required for attachment of the henipavirus virion to the target cell, the F 
glycoprotein is responsible for the merger of the viral membrane envelope with the target cell   
plasma membrane. The F glycoprotein is initially expressed as a 546 amino acid precursor (F0) which 
forms an oligomeric trimer that is cleaved into two subunits (F1 and F2) by the endosomal protease 
cathepsin L [75]. Unique to the henipaviruses, the processing of F0 into its biologically active form is a 
multi-step process requiring recycling of F0 from the cell surface into an endosomal compartment, 
mediated by an enodcytosis motif present in the cytoplasmic tail of F [76,77]. Interestingly, HeV and 
NiV-F glycoproteins contain no specific cleavage sequence, and cleavage is only inhibited by the 
deletion of six residues upstream of the cleavage site [78]. After cleavage, the homotrimer of disulfide 
bond linked F1 and F2 subunits is trafficked back to the cell surface. 
The F1 subunit contains several important structural characteristics that include an N-terminal 
hydrophobic fusion peptide domain, two heptad repeat (HR) domains, a transmembrane domain and 
cytoplasmic tail. The two α-helical heptad repeat domains reside immediately downstream of the fusion 
peptide (HR1 or HRA) and upstream (HR2 or HRB) of the transmembrane domain and are the shortest 
HR domains among paramyxoviruses [79]. The C-terminal cytoplasmic tail and the transmembrane 
domain have also recently been implicated in modulating virus-mediated fusion as tyrosine residues in 
the tail have been shown to increase fusion activity and aid in the proper trafficking of F in polarized 
epithelial cells [80,81]. Viruses 2012, 4  
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4.1. The Fusion Mechanism 
The crystal structures of the paramyxovirus F glycoproteins (SV5 and human parainfluenza virus 3 
(hPIV3)) have provided significant insight into the mechanism of the fusion process and the structural 
transition that occurs between the pre- and post-fusion conformations of F [82,83]. Although the 
paramyxovirus F glycoproteins resemble other Class I viral fusion glycoproteins, they are distinctly 
structurally different in comparison to other pre- and post-fusion Class I viral fusion glycoprotein 
structures, and the hPIV3-F and PIV5-F structures are the only available models for making good 
comparisons of the paramyxovirus F structural transition [84]. Prior to receptor binding, the hydrophobic 
fusion peptide located at the N-terminus of the F1 subunit is concealed in the protein. Upon receptor 
binding, the paramyxovirus attachment glycoprotein promotes F fusion activity by an as yet ill-defined 
mechanism, triggering irreversible conformational changes in F that (1) expose the fusion peptide, 
allowing it to be inserted into the opposing target cell membrane and (2) rearrange the HR domains, 
leading to the formation of the hallmark feature of Class I fusion—the six helix bundle (6 HB) 
(recently reviewed [39,85]). This process is a multi-step event that results in the elongation of F as well 
as the merger of the viral and cellular membranes. The assembly of the 6 HB is believed to provide the 
energy required for the membrane destabilization and merger event as the three HR2 domains within 
the F trimer are rearranged to bind via hydrophobic interactions in the grooves of the trimeric core 
composed of the HR1 domains [79]. However, the number of F homotrimers required for fusion pore 
formation and membrane merger is unknown.  
5. G and F Glycoprotein Interaction 
Although recombinant forms of the paramyxovirus respiratory syncytial virus (RSV) and the F 
glycoprotein of SV5 are capable of mediating membrane fusion activity in the absence of their   
co-expressed G glycoprotein partner, the majority of paramyxoviruses, including the henipaviruses, 
require their attachment glycoprotein to promote F-mediated membrane fusion [86–88]. Despite the 
requirement of receptor engagement by henipavirus G to initiate fusion, the interaction of G and   
F appears independent of receptor binding as G and F can be co-precipitated in the absence of receptor 
[48,56,89,90]. It has been shown that several paramyxovirus F and attachment glycoprotein pairs, 
including those from MeV, NDV and hPIV2, first interact in the endoplasmic reticulum (ER) [91–94]. 
However, for other viruses (SV5 and hPIV3) an F and HN interaction prior to fusion was earlier 
suggested to not be robust [95], and here these viral F glycoprotein fusion systems do not suggest a 
model whereby the F and attachment glycoproteins are pre-associated (discussed in Section 6). 
Further, the henipavirus G and F glycoproteins have different and more complex trafficking patterns in 
comparison to other paramyxoviruses. The HeV and NiV-G have been shown to take longer than their 
partner F glycoprotein to traffic through the ER and Golgi, and this longer trafficking time of G and 
the complex pattern of F maturation suggests that G-F interaction does not occur until both 
glycoproteins are expressed on the cell membrane [91,96].  
Although most evidence indicates that the G and F glycoproteins interact prior to G-ephrin receptor 
binding, the exact nature of this interaction and the domain(s) of G and F that associate are not well 
defined. Bishop et al. found that mutations at specific sites in the stalk domain of HeV-G inhibited Viruses 2012, 4  
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HeV fusion due to an apparent loss of interaction with F [51]. These particular isoleucine residues are 
located in an alpha helical domain that resembles a heptad repeat that is highly conserved among 
paramyxoviruses [51]. Interestingly, the nine Ile→Ala mutations that abolished the fusion promoting 
activity of HeV-G are located near the region that Yuan et al. have implicated as important for the 
tetramer formation of NDV HN (Figure 1 and discussed above) [49,51]. Monoclonal antibody (mAb) 
binding analysis, with several mAbs that preferentially recognize G in complex with ephrin receptor, 
revealed that these HeV-G stalk domain mutants appeared to adopt a receptor-bound conformation in 
the absence of receptor binding and thus were unable to trigger F fusion activation even upon any 
subsequent ephrin receptor binding. These observations suggest that G must be in some correct   
pre-receptor bound tetrameric conformation in order to properly trigger F fusion activity and also 
indicate that receptor binding and fusion triggering by G can be uncoupled.  
6. Model of Henipavirus Fusion 
Two principal models of paramyxovirus glycoprotein-mediated membrane fusion have been 
postulated [97] (recently reviewed [85]). In the first model, the F glycoprotein and the attachment 
glycoprotein are not physically associated in the membrane, but following receptor engagement there 
is an alteration in the attachment protein which facilitates its association with F and in so doing imparts 
or triggers/induces the F glycoprotein conformational changes leading to membrane fusion. This 
association or provocateur scenario has been supported by extensive functional and structural studies 
on the HN and F glycoproteins of hPIV3, NDV and PIV5 [49,95,98–100]. In the second model, the 
dissociation or clamp model, the F and attachment glycoproteins are pre-associated and a 
conformational alteration in the latter following receptor engagement alters or releases F allowing it to 
proceed towards the fusion active state and 6 HB formation, supported by studies with the MeV-H and  
-F glycoproteins [73,92,101]. 
The preponderance of data suggests that there does appear to be two major ways that 
paramyxoviruses have evolved to regulate F fusion activation; one represented by those employing an 
HN-F glycoprotein pair and the other represented by the H-F glycoprotein pair (recently reviewed in 
detail elsewhere [39,102,103]). However, in either case it would seem plausible that upon triggering 
the F glycoprotein and initiating its conformational changes leading to 6 HB formation, F would need 
to be free of any association with its large oligomeric partner—HN, H or G. For the henipaviruses, the 
findings to date suggest that HeV and NiV initiate fusion by a mechanism more in line with a clamp 
model. In this scenario F could be stabilized in some manner by interaction with G, perhaps maintaining 
F in a pre-fusion state, or it could just simply be that G and F have some propensity to specifically 
interact until receptor binding to G initiates some specific interaction with F triggering fusion activity 
and then followed by dissociation, much like a provocateur model.  
In support of a general clamp model for henipavirus fusion, it has been observed that the strength of 
G-F interaction is inversely proportional to fusion activity as stronger G-F interaction results in 
decreased fusion due to the inability of F to disassociate from G [56,89,104]. These observations are in 
agreement with the earlier suggestion that the henipavirus-mediated fusion mechanism is similar to 
MeV, which also exhibits an inverse relationship between the attachment glycoprotein (H) and F [101]. 
Also in accord with this fusion model are the observations that both MeV and HeV possess attachment Viruses 2012, 4  
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glycoproteins that with certain mutations decrease their receptor binding activity while strengthening 
the interactions with their respective F glycoprotein partner [56,105].  
Indirect support for the provocateur model also comes from data indicating that F expressed in the 
absence of G can be recognized by a conformation-dependent mouse mAb specific for the pre-fusion 
form of NiV-F [106]. These conflicting data suggest that neither a clamp model nor a provocateur 
model alone can fully account for all the experimental observations to date on the mechanism of 
henipavirus-mediated fusion. In fact, a recent report by Porotto et al. details a new, third fusion 
mechanism that is based on both the clamp and provocateur models [107]. Their new model is based 
on the need for continuous receptor engagement by hPIV3-HN to activate F for membrane fusion [107]. 
In this study, fusion intermediates were captured by using HR2 peptides localized in the target cell 
membrane by a cholesterol tag. It was determined that if interaction between hPIV3-HN and its 
receptor was interrupted during F activation and insertion into the target membrane, fusion would not 
occur. However, no direct HN-F interactions were assessed, such as through a co-association or a  
co-immunoprecipitation approach. Most recently, a further study by Porotto et al., examined the hPIV3 
fusion system using a bimolecular fluorescence complementation approach to follow the dynamics of 
the viral HN and F in living cells [108]. The authors were able to demonstrate that in this system the 
HN and F glycoproteins do associate prior to receptor engagement, HN drives the formation of HN and 
F interacting clusters at the site of membrane fusion and the interaction of the HN-F pairs of oliogmers 
modulate the viral glycoprotein pair’s fusogenicity [108]. This requirement of continual receptor 
engagement and interaction between the attachment and fusion glycoproteins was hypothesized to be 
applicable to all paramyxoviruses, including HeV and NiV [107]. Further research regarding this 
proposed mechanism in respect to HeV/NiV may be able to resolve the conflicting data supporting the 
two current models and clarify the mechanism of henipavirus-mediated fusion.  
7. Therapeutics 
Licensed and efficacious antiviral therapeutics for the henipaviruses are currently not available. 
Ribavirin was used to treat 140 patients during the NiV outbreak in Malaysia in 1998/99, lessening the 
mortality rate by 35% from 54% in the control group to 32% in the treated group [109]. Without any 
other currently available therapeutic options, ribavirin is still considered an option for treatment, but its 
impact on disease progression is questionable as two HeV infected patients in 2008 showed no 
discernable benefit after treatment with ribavirin [8]. Additionally, chloroquine, an anti-malarial drug 
first demonstrated to block the proteolytic processing of HeV-F [110], was later shown to inhibit 
henipavirus infection in vitro [111]. However, treatment with chloroquine and ribavirin proved 
ineffective for one HeV-infected individual in 2009 as no clinical benefit was observed [112]. 
In subsequent animal challenge models with henipaviruses, ribavirin only delayed NiV disease and 
death and had no therapeutic effect against HeV infection in hamsters [113,114]. Ribavirin also 
only  delayed HeV disease by 1 or 2 days in African green monkeys and did not prevent disease   
outcome [115]. Chloroquine, either alone or in combination with ribavirin, also had no therapeutic 
benefit in ferrets challenged with NiV or hamsters challenged with either NiV or HeV [113,116]. Thus, 
due to the extreme pathogenic capacity of HeV and NiV infection in people, considerable effort has 
been spent in developing and exploring new therapeutic options against the henipaviruses, and these Viruses 2012, 4  
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treatments have primarily focused on targeting the fusion and entry step of the virus infection process 
and include F glycoprotein-targeted peptide fusion inhibitors and passive immunotherapy with virus 
neutralizing mAbs targeting the G and F glycoproteins. Here we highlight the recent developments in 
therapeutics that target virus entry which have shown promise in treating henipavirus infection and 
pathogenesis. 
7.1. Peptide Fusion Inhibitors and Premature Fusion Triggering 
Heptad peptide based fusion inhibitors corresponding to HR1 or HR2 domains of a viral fusion 
protein have been shown to be particularly effective at inhibiting pH-independent Class I viral fusion 
systems in vitro, such as with paramyxoviruses, when present prior to triggering the fusion process 
leading to the formation of the 6 HB (reviewed in [117]). Most of these approaches have utilized 
peptides corresponding to the HR2 domain, and they act by blocking 6 HB formation by binding in the 
grooves of the HR1 trimeric core and prevent the viral HR2 domains from binding. The first promising 
henipavirus-specific therapeutic was a 36 amino acid HR2-based fusion inhibitor (NiV-Fc2) [118] 
analogous to the approved HIV-1 specific therapeutic peptide enfuvirtide (Fuzeon™). Addition of 
exogenous NiV-Fc2 peptide could potently block HeV and NiV membrane fusion and live virus 
infection [118,119]. The effectiveness of the NiV-Fc2 fusion inhibitor against henipavirus infection  
in vivo in a suitable animal model is presently being evaluated [120].  
While some approaches have focused on optimizing the length and sequence of exogenous HR2 
peptides to increase their efficacy, one study determined that an HR2 peptide derived from hPIV3 
proved more effective at inhibiting henipavirus mediated fusion than a peptide derived from HeV  
HR2 [121,122]. The increased efficacy of the hPIV3 peptide appears to be due to stronger interactions 
between the hPIV3 HR peptide and the binding grooves of the HR1 domains than HR peptides 
corresponding to the native henipavirus F HR2 peptide sequence. More recently, these observations 
were followed up with testing of a sequence-optimized and cholesterol tagged hPIV3-based   
HR2-derived peptide that targets hPIV3 and henipavirus F in the hamster-model of NiV infection [123]. 
Here, these cholesterol-tagged peptides could also penetrate the CNS and exhibit some effective 
therapeutic activity against NiV infection in the hamster model; this peptide approach could be 
particularly effective in treating the encephalitic manifestations of henipavirus infection.  
While there appears to be potential for peptide fusion inhibitors to be highly effective in preventing 
infection, there remains numerous challenges to overcome in the design and administration of such a 
therapeutic protocol. The peptide based fusion inhibitors should likely be small and soluble with a long 
half-time in the bloodstream, but they must still be able to specifically bind the heptad repeats in their 
target F glycoprotein in order to block 6 HB formation and membrane fusion. The time frame of 
effective use of peptide fusion inhibitors may also be narrow because these inhibitors are only effective 
if present prior to 6 HB formation but after the fusion peptide has been inserted into the target cell 
membrane. In addition, as with most antiviral therapeutics, peptide inhibitors would also face resistance 
problems since mutations may likely arise within the heptad repeat sequences of the F glycoprotein. 
Despite these challenges, additional in vivo efficacy testing of peptide fusion inhibitors of henipavirus 
infection merits further investigation.  Viruses 2012, 4  
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Recognizing that conformational changes occur in both G and F upon receptor binding, it was 
suggested earlier from mutagenesis results on HeV-G that a fusion triggered conformation could be 
generated in the absence of receptor, and thereby render the F-G complex ineffective (discussed   
above) [51]. Recently, Porotto et al. demonstrated that protocells expressing ephrin-B2 were capable 
of inactivating NiV-F and -G expressing pseudovirus by premature fusion triggering [124]. Similarly,  
it was demonstrated early on that soluble ephrin-B2 henipavirus receptor was capable of blocking 
fusion and virus entry, but its antiviral activity was presumed to be due to simply blocking virus-host 
cell engagement rather than also serving as a premature fusion trigger [53,54]. Not surprisingly, it was 
also shown that recombinant soluble versions of the ephrin-B2 receptors (EphB4 and EphB2) could 
also block henipavirus-mediated membrane fusion by binding to ephrin-B2 on the host cell making it 
unavailable for G glycoprotein binding [54]. Finally, the scenario of premature fusion triggering as a 
potential therapeutic approach was presented with the identification of a small molecule capable of 
binding hPIV3 HN and triggering F to undergo conformational change in the absence of receptor 
binding, again rendering this paramyxovirus glycoprotein pair ineffective and further suggesting that 
strategies aimed at premature fusion activation may be a viable and interesting antiviral strategy [125].  
7.2. Monoclonal Antibodies 
For paramyxoviruses, antibodies specific for either the F or attachment glycoproteins can neutralize 
virus with antibodies directed against attachment glycoproteins typically being the more predominant 
(reviewed in [126]). The first evidence of passive protection against a NiV challenge was demonstrated 
using hamsters with monospecific polyclonal antiserums against F and G [127]. Passive immune 
plasma therapy was also successful in the post-exposure treatment of African green monkeys infected 
with NiV [120]. However, the development of virus neutralizing mAbs has made passive antibody 
therapy development a major focus of current research. Another passive immunotherapy study in the 
hamster model using two murine mAbs against NiV-F and two against G was shown to completely 
protect the challenged animals if animals received mAbs before and immediately following challenge, 
and again, mAbs targeting the G glycoprotein proved more effective than mAbs targeting the F 
glycoprotein [128]. Similar results were also obtained in a HeV challenge model in the hamster [129]. 
A major advance in the development of specific mAbs has been the use of recombinant antibody 
technologies [130,131]. Earlier, recombinant, soluble G (sG) glycoprotein from HeV was used to 
isolate human mAbs. One particular human mAb (m102.4) was HeV and NiV cross-reactive and 
possessed extremely potent virus neutralizing activity [132,133]. In vivo studies have since demonstrated 
that m102.4 can protect animals from a lethal challenge with henipaviruses as a post-exposure 
application in the ferret model with NiV [134] or HeV [135]. Most recently, mAb m102.4 was tested 
in the African green monkey model against HeV, and again all animals could be protected from lethal 
disease by m102.4 when it was administered from 12 to as late as 72 hours after a lethal high dose 
intratracheal challenge [136]. In August 2009, m102.4 was used on a compassionate basis to save the 
life of a HeV-infected individual while in a coma [137]. Unfortunately, delivery and intravenous 
administration of only 100 mg of available antibody occurred after the onset of encephalitis and the 
individual died shortly thereafter. However, during the 2010 HeV emergence, prior to HeV diagnosis 
or the onset of clinical disease, two individuals that were considered as high risk cases of possible Viruses 2012, 4  
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infection received m102.4 antibody at doses sufficient to achieve a high serum concentration, and both 
individuals have remained healthy [138]. Together, these findings highlight the therapeutic potential of 
mAb-based passive transfer modalities for treating henipavirus exposure. Presently, m102.4 is being 
developed further for clinical use in people.  
The mechanism and efficacy of m102.4-mediated neutralization is likely due to its ability to directly 
compete with ephrin-B2 and -B3 receptors for binding to the HeV and NiV-G glycoprotein. Indeed, 
this seems born out when a comparison of the G glycoprotein binding pockets used by m102.4 and 
ephrin-B2 and -B3 is made, which shows a remarkable series of identical contacting residues in G that 
are important for engaging the ephrins as well as mAb m102.4 (Figure 3) [139]. Substituting for the  
G-H loop of ephrin-B2 and -B3, m102.4 has a stretch of amino acid residues (L105APHPS110) that bind 
the henipavirus G glycoprotein with four residues considered critical for binding (L105, P107, H108 
and P109).  
Figure 3. HeV-G residues that bind ephrin and monoclonal antibody m102.4.   
A monomeric unit of the globular head of HeV-G (gray) is shown with residues important 
for ephrin-B2 and -B3 binding highlighted in purple, residues required for binding mAb 
m102.4 shown in blue and the residues of the ephrin-B2 G-H loop in yellow. While the 
conformations of the residues may be slightly different, almost every residue involved in 
binding ephrin-B2 and -B3 is also required for binding m102.4, suggesting m102.4 
prevents HeV and NiV infection by preventing ephrin-B2 and -B3 binding.  
 Viruses 2012, 4  
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8. Concluding Remarks 
The henipaviruses present credible natural and potentially deliberate biothreats to human and 
livestock populations. While our knowledge of the viral mechanisms involved in the infection process 
has increased there are still many unanswered questions. Through mutational studies it has been shown 
that receptor binding alone to G is not sufficient to trigger the F glycoprotein-mediated membrane 
fusion process. Rather, receptor engagement and membrane fusion appear to be two separate but 
connected steps as receptor engagement does appear to trigger conformational changes in G that likely 
lead to the activation of the fusion activity of F. While the crystal structures of the henipavirus G 
glycoproteins both alone and in complex with receptor have helped to identify the critical residues for 
receptor binding as well as some of the conformational changes induced by receptor binding, further 
studies will be required to determine the overall conformational changes that occur in the native 
tetrameric structure that are also postulated to lead to activation of F.  
In addition, the specific interactions between the henipavirus G and F glycoproteins, including those 
that are specifically required for F activation, still need to be clarified. Adding further complexity to G 
and F interaction and the fusion mechanism is the recently proposed model of paramyxovirus fusion 
that suggests fusion activation involves receptor engagement for F activation but also continual   
F-interaction by the receptor-bound G glycoprotein [107]. Whether the henipavirus membrane fusion 
process aligns more with the clamp, provocateur or continual engagement fusion model (or a 
combination of these) will require further clarification. Finally and perhaps most importantly, the 
development of human mAbs that potently inhibit the glycoprotein-mediated entry of these viruses into 
cells has for the first time provided a safe and effective therapeutic strategy, which is currently being 
used for treatment of people in emergency situations.  
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